Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis and Therapy.
JAMA, 285 (2001), pp. 785-795
[2.]
N.F. Ray, J.K. Chan.
Thamer, M. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from The National Osteoporosis Fundation.
J Bone Mineral Res, 12 (1997), pp. 24-35
[3.]
Physician's Guide to Prevention and Treatment of Osteoporosis.
[4.]
Sociedad Española de Investigaciones Óseas y Metabolismo Mineral (SEIOMM).
Osteoporosis postmenopáusica.
Guía de Práctica Clínica, (2001),
[5.]
K.B. Faulkner.
Bone matters: Are density increases necessary to reduce fracture risk?.
J Bone Miner Res, 15 (2000), pp. 183-187
[6.]
R.D. Wasnich, P.D. Miller.
Antifracture efficacy of antiresorptive agents are related to changes in bone density.
J Clin Endocrinol Metab, 85 (2000), pp. 231-236
[7.]
I.I.I. Melton LJ, E.J. Alkinson, C. Cooper.
Vertebral fractures predict subsequent fractures.
Osteoporos Int, 10 (1999), pp. 214-221
[8.]
D.M. Black, N.K. Arden, L. Palermo.
for the Study of Osteoporosis Fractures Research Group. Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures.
J Bone Mineral Res, 14 (1999), pp. 821-828
[9.]
R. Lindsay, S.L. Silverman, C. Cooper, J.A. Cauley.
Risk of new vertebral fracture in the year following a fracture.
JAMA, 285 (2001), pp. 320-323
[10.]
K.E. Endsrud.
Thompson DE (Fracture Intervention Trial Research Group) Prevalent vertebral deformities predict mortality and hospitalization in older women with low bone mass.
J Am Geriatr Soc, 48 (2000), pp. 241-249
[11.]
D.C. Bauer.
Osteoporotic fractures: ignorance is bliss?.
Am J Med, 109 (2000), pp. 338-339
[12.]
K.B. Freedman, F.S. Kaplan, W.B. Bilker.
Treatment of osteoporosis: are physicians missing an opportunity?.
J Bone Joint Surg A.m, 82A (2000), pp. 1063-1070
[13.]
WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Geneva: WHO Technical Report Series n.° 843
[14.]
AACE 2001 Medical Guidelines for clinical practice for the prevention and management of postmenopausal osteoporosis.
Endocr Prac, 7 (2001), pp. 294-312
[15.]
B. Riis, K. Thomsen, C. Christiansen.
Does calcium supplementation prevent postmenopausal bone loos? A double-blind controlled clinical study.
N Engl J Med, 316 (1987), pp. 173
[16.]
M.J. Grainge, C.A. Coupland, S.J. Cliffe, C.E. Chilvers, D.J. Hosting.
(Nottinghan EPIC Study Group). Cigarette smoking, alcohol and caffeine comsumption, and bone mineral density in postmenopausal women.
Osteoporos Int, 8 (1998), pp. 355-363
[17.]
M.C. Chapuy, M.E. Arlot, F. Duboeuf.
Vitamin D3 calcium to prevent hip fractures in elderly women.
N Engl J Med, 327 (1992), pp. 1637
[18.]
P. Mezquita Raya, M. Muñoz-Torres.
Relation between vitamin D insufficiency, bone density, and bone metabolism in healthy postmenopausal women.
J Bone Miner Res, 16 (2001), pp. 1408-1415
[19.]
R.L. Prince, M. Smith, M. Dick.
Prevention of postmenopausal osteoporosis: a comparative study of exercise, calcium supplementation, and hormone-replacement therapy.
N Engl J Med, 325 (1991), pp. 1189
[20.]
C.W. Slemenda, C. Longcope, L. Zhou.
Sex steroids and bone mass in older men. Positive associations with serum estrogens and negative associations with androgens.
J Clin Invest, 100 (1997), pp. 1755
[21.]
H.M. Behre, S. Kliesch, E. Leifke.
Long-term effect of testosterone therapy on bone mineral density in hypogonadal men.
J Clin Endocrinol Metab, 82 (1997), pp. 2386
[22.]
M. Muñoz-Torres, P. Mezquita Raya.
The contribution of IGF-I to skeletal integrity in postmenopausal women.
Clin Endocrinol, 55 (2001), pp. 759-766
[23.]
M. Ortego, M. Muñoz-Torres.
Bone mineral density, sex steroids, and mineral metabolism in premenopausal smokers.
Calcif Tissue Int, 55 (1994), pp. 403-407
[24.]
P.D. Delmas, N.H. Bjarnason, B.H. Mitlak.
Effects of raloxifene on bone mineral density, serum cholesterol concentrations and uterine endometrium in post menopausal women.
N Engl J Med, 337 (1997), pp. 1641-1647
[25.]
R.J. Herd, R. Balena, G.M. Blake, P.J. Ryan, I. Fogelman.
The prevention of early postmenopausal bone loss by cyclical etidronate therapy: a 2-year, double-blind, placebo-controlled study.
Am J Med, 103 (1997), pp. 92-99
[26.]
L. Mortensen, P. Charles, P.J. Bekker, J. Digennaro, C.C. Johnston Jr..
Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up.
J Clin Endocrinol Metab, 83 (1998), pp. 396-402
[27.]
D. Hosking, C.E.D. Chilvers, C. Christiansen, P. Raun, R. Wasnick, P. Ross, et al.
Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group.
N Eng J Med, 338 (1998), pp. 485-492
[28.]
AACE clinical practice guidelines for the prevention and treatment of postmenopausal osteoporosis.
J Flo Med Assoc, 83 (1996), pp. 552-565
[29.]
P. Maxim, B. Ettinger, G.M. Spitalny.
Fracture protection provided by long-term estrogen treatment.
Osteoporos Int, 5 (1995), pp. 23-29
[30.]
N. Santoro, N.T. Miller.
Menopause and the menopausal state.
Curr Pract Med, 1 (1998), pp. 423-428
[31.]
M. Muñoz-Torres, P. Mezquita.
Nuevos planteamientos en el papel de los estrógenos sobre el metabolismo óseo.
Med Clín (Barc), 113 (1999), pp. 292-293
[32.]
C.J. Rosen, C.R. Kessenich.
The pathophysiology and treatment of postmenopausal osteoporosis: an evidence-based approach to estrogen replacement therapy.
Endocrinol Metab Clin North Am, 26 (1997), pp. 295-311
[33.]
J.E. Manson, K.A. Martin.
Postmenopausal hormone-replacement therapy.
N Engl J Med, 345 (2001), pp. 34-40
[34.]
D. Torgenson, S.E.M. Bell Syer.
Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials.
JAMA, 285 (2001), pp. 2891-2897
[35.]
M. Clemons, P. Goss.
Estrogen and the risk of breast cancer.
N Engl J Med, 344 (2001), pp. 276-285
[36.]
H.K. Genant, J. Lucas, S. Weiss.
For the Estratab/Osteoporosis Study Group. Low-dose esterified estrogen therapy: effects on bone, plasma estradiol concentrations, endometrium and lipid levels.
Arch Intern Med, 157 (1997), pp. 2609-2615
[37.]
R.R. Recker, K.M. Davis, R.M. Dowd.
The effect of low-dose continuos estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women: a randomized, controlled trial.
Ann Intern Med, 130 (1999), pp. 897-904
[38.]
L.V. Avioli.
The role of calcitonin in the prevention of osteoporosis.
Endocrinol Metab Clin North Am, 27 (1998), pp. 411-418
[39.]
K. Overgaard, M.A. Hansen, S.B. Jensen.
Effect of calcitonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study.
BMJ, 305 (1992), pp. 556-561
[40.]
M. Muñoz Torres, P. Mezquita.
La calcitonina.
Drugs Today, 35 (1999), pp. 1-12
[41.]
I.I.I. Chesnut CH, S. Silverman, K. Andriano.
for The PROOF Study Group. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The Prevent Recurrence of Osteoporotic Fractures Study.
Am J Med, 109 (2000), pp. 267-276
[42.]
S.R. Cummings, R.D. Chapurlat.
What PROOF proves about calcitonin and clinical trails.
Am J Med, 109 (2000), pp. 330-331
[43.]
U.A. Liberman, S.R. Weiss, J. Bröll.
For The Alendronate Phase III Osteoporosis Treatment Study Group. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis.
N Engl J Med, 333 (1995), pp. 1437-1443
[44.]
M. Favus, R. Emkey, M. Leite.
Five-year treatment of osteoporosis in postmenopausal women with oral alendronate: effects on bone mass and turnover and safety.
J Bone Miner Res, 12 (1997), pp. S150
[45.]
R.P. Tonino, P.J. Meunier, R. Emkey.
for the Alendronate Phase III Osteoporosis Treatment Study Group. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women.
J Clin Endocrinol Metab, 85 (2000), pp. 3109-3115
[46.]
D.M. Black, S.R. Cummings, D.B. Karf.
Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures.
Lancet, 348 (1996), pp. 1535-1541
[47.]
S.R. Cummings, D.M. Black, D.E. Thompson.
Effect of alendronate on risk fracture in women with low bone density but without vertebral fractures.
JAMA, 280 (1998), pp. 2077-2082
[48.]
H.A.P. Pols, D. Felsenberg, D.A. Hanley, J. Stepan, M. Muñoz-Torres.
A multinational randomized trial of the effects of Alendronate on bone mineral density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT Study.
Osteoporos International, 9 (1999), pp. 461-468
[49.]
D.B. Karpf, D.R. Shapiro, E. Seeman.
Prevention of non-vertebral fractures by alendronate: a meta-analysis.
JAMA, 277 (1997), pp. 1159-1164
[50.]
T. Schnitzer, H.G. Bone, G. Crepaldi.
for the Alendronate Once-Weekly Study Group. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis.
Aging Clin Exp Res, 12 (2000), pp. 1-12
[51.]
J-Y Reginster, H.W. Minne, O.H. Sorensen.
For The Vertebral Efficacy With Risendronate Therapy (VERT) Study Group.
Osteoporosis Int, 11 (2000), pp. 83-91
[52.]
S.T. Harris, N.B. Watts, H.K. Genant.
for the Vertebral Efficacy With Risendronate Therapy (VERT) Study Group. Effects of risendronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a ramdomized, controlled trial.
JAMA, 282 (1999), pp. 1344-1352
[53.]
M.R. McClung, P. Gensens, P.D. Miller.
for the Hip Intervention Program Study Group. Effect of risendronate on the risk of hip fracture in elderly women.
N Engl J Med, 344 (2001), pp. 333-340
[54.]
M. Muñoz-Torres, P. Mezquita, F. López-Rodríguez.
Moduladores selectivos de los receptores estrogénicos.
Actualización de Osteoporosis, pp. 135-143
[55.]
C.P. Spencer, E.P. Morris, J.M. Rymer.
Selective estrogen receptor modulators: women's panacea for the next millennium?.
Am J Obstet Gynecol, 180 (1999), pp. 763-770
[57.]
B. Ettinger, D.M. Black, B.H. Mirtlak.
for the Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial.
JAMA, 282 (1999), pp. 637-645
[58.]
S.R. Cummings, S. Eckert, K.A. Krueger.
The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial.
JAMA, 281 (1999), pp. 2189-2197
[59.]
J.A. Cauley, L. Norton, M.E. Lippman.
Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial.
Breast Cancer Res Treat, 65 (2001), pp. 125-134
[60.]
E. Barret-Connor, D. Grady, A. Sashegyi.
Raloxifene and cardiovascular events in osteoporotic postmenopausal women.
JAMA, 287 (2002), pp. 847-857
[61.]
F. Cosman, R. Lindsay.
Is parathyroid hormone a therapeutic option for osteoporosis? A review of the clinical evidence.
Calcif Tissue Int, 62 (1998), pp. 475-480
[62.]
P. Morley, J.F. Whitfield, G.E. Willick.
Parathyroid hormone: an anabolic treatment for osteoporosis.
Curr Pharm Des, 7 (2001), pp. 671-687
[63.]
R.M. Neer, C.D. Arnaud, J.R. Zanchetta.
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
N Engl J Med, 344 (2001), pp. 1434-1441
[64.]
E.S. Kurland, F. Cosman, D.J. McMahon, C.J. Rosen, R. Lindsay, J.P. Bilezikian.
Parathyroid hormone as a therapy for idiophatic osteoporosis in men: effects on bone mineral density and bone markers.
J Clin Endocrinol Metab, 85 (2000), pp. 3069-3076
[65.]
N.E. Lane, S. Sánchez, G.W. Modin, H.K. Genant, E. Pierini, C.D. Arnaud.
Parathyroid-hormone treatment can reverse corticosteroid-induced osteoporosis.
J Clin Invest, 102 (1998), pp. 1627-1633
[66.]
D.W. Dempster, F. Cosman, E.S. Kurland, H. Zhou, J. Nieves, L. Woelfert, et al.
Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study.
J Bone Miner Res, 16 (2001), pp. 1846-1853
Copyright © 2003. Elsevier España, S.L.. Todos los derechos reservados